Alpenglow Biosciences, a leader in AI-powered 3D pathology, today announced a strategic agreement with Virdx, a biophysics AI ...

At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...

Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 2015, ...

Three years later, Massey patients are still benefiting from MRIdian’s precision technology, now evidenced in prostate cancer ...

Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy. Background: Prostate cells released into expressed prostatic secretions (EPS) during ...

AIIMS radiologist stresses importance of early prostate cancer screening, starting at age 50, or earlier for those with risk factors, for effective management.

Alpenglow Biosciences collaborates with Virdx to advance AI-enabled prostate cancer diagnostics: Seattle Thursday, October 9, 2025, 09:00 Hrs [IST] Alpenglow Biosciences, a leader ...